{
    "ucits": true,
    "type": "ETF",
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "replication_method": "physical",
    "complex_factors": "None identified",
    "classification": "non-complex",
    "supporting_data": "The L&G Healthcare Technology & Innovation UCITS ETF is a UCITS-compliant, physically replicated ETF tracking a transparent equity index. It primarily invests in the underlying securities of the index, with no evidence of synthetic replication, significant derivative use, leverage, swaps, or inverse strategies. The fund may use financial derivative instruments (FDIs) for efficient portfolio management, but there is no indication these are central to the investment objective or introduce material counterparty or collateral risk. The structure, risks, and payoff are straightforward and consistent with typical equity UCITS ETFs. The fund is not leveraged beyond UCITS limits, does not embed complex options or structured products, and does not hold contingent convertible bonds or other complex securities. The index is transparent and the fundu2019s documentation is comprehensive and accessible. All these factors support a non-complex classification under MiFID II Article 25(4) and Delegated Regulation Article 57, as UCITS ETFs are generally presumed non-complex unless specific complex features are present, which are not evident here[1]. ESMA and CESR guidance confirms that physical replication and limited derivative use for hedging do not typically trigger complexity for UCITS ETFs, provided the risks remain transparent and the product is easily understood by retail investors[2]."
}